The Immunotherapy Segment is expected To Dominate the Global Exosome Therapeutics Market Growing with the Highest CAGR Of 17.5%

Oncology has a significant impact across the world. The rise in the incidence of oncology diseases is due to change in lifestyle and an increase in lifespan. With their natural delivery abilities, the exosomes have been successfully used as a drug and functional RNA delivery vectors for cancer treatment. As cancer incidence is increasing in all regions, the use of exosome therapeutics is also growing. The exosomes derived from various sources encapsulate the drugs and deliver therapeutic agents such as small molecule drugs, nucleic acids, and proteins to cancer cells by passive or active targeting. The exosomes would extend the half-life of the drug. Therefore, the rise in incidences of oncology diseases is expected to drive the global exosome therapeutics market growth.

Data Bridge Market Research analyses that the exosome therapeutics market is expected to grow at a CAGR of 16.9% in the forecast period of 2021 to 2028 and is expected to reach USD 1,602.54 million by 2029. As the market players are constantly engaged in research and developmental activities, more hybrid and natural exosomes are being introduced in the global exosome therapeutics market. This would increase the demand for exosome therapeutics to treat cancer and autoimmune diseases in hospitals and diagnostic centers. Hence the advancements in research and development activities are expected to drive market growth.

Exosome Therapeutics Market

Surge in funding for Production and Deployment of Exosome Therapeutics globally is expected to drive the market's growth rate

Government funding refers to financial assistance received by nongovernment entities through federal, state, or local government grants. The funding received by the nongovernment entities would be used for the development of exosomes therapeutics. This increases the overall supply of the therapeutics, which l owners the overall price of the good or service. The government's funding would result in patient safety, cost savings, and lower the financial impact of surgical care. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Therefore, the government funded the development and production of exosomes, which is expected to drive the global exosome therapeutics market.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020(Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Natural Exosome, Hybrid Exosome), Source (Mesenchymal Stem Cells, Blood, Body Fluids, Urine, Dendritic Cells, Saliva, Milk, and Others), Therapy (Immunotherapy, Chemotherapy, and Gene Therapy), Transporting Capacity (Bio Macromolecules and Small Molecules), Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, Blood Disorders, and Others), Route of administration (Parenteral and Oral), End User (Research and Academic Institutes, Hospitals and Diagnostic Centers)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Church & Dwight Co., Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (U.S.), AstraZeneca (U.S.), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (U.S.), CELGENE CORPORATION (U.S.), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (U.S.), among others

Data Points Covered in Report

In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The global exosome therapeutics market is categorized into seven notable segments which are based on type, source, therapy, transporting capacity, application, route of administration and end user.

  • On the basis of type, the global exosome therapeutics market is segmented into natural exosomes and hybrid exosomes. The natural exosomes is further sub-segmented into autologous exosomes and exogenous exosomes. In 2022, the natural exosomes segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 16.9%

The natural exosomes segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 16.9%

In 2022, the natural exosomes segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 16.9% in the forecast period of 2022 to 2029 due to the presence of natural material of the exosomes and instrumentation and reduced cost of production.

  • On the basis of source, the global exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva milk and others. In 2022, the mesenchymal stem cell segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 16.8%in the forecast period of 2022 to 2029 due to emerging applications of mesenchymal stem cells and expansion of pipeline and clinical studies of mesenchymal stem cells based products.
  • On the basis of therapy, the global exosome therapeutics market is segmented into immunotherapy, gene therapy and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 17.5% in the forecast period of 2022 to 2029 due to ease of convenience, high accuracy and improvement in long tern survival rate.
  • On the basis of transporting capacity, the global exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 17.1% in the forecast period of 2022 to 2029 due to presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders, cancer and ease of availability.
  • On the basis of application, the global exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders and others. In 2022, the metabolic disorders segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 17.6% in the forecast period of 2022 to 2029 due to the increase in cases of metabolic disorders, availability of exosome therapeutics or metabolic disorders and increase in demand for one-time therapies.
  • On the basis of route of administration the global exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 16.9% in the forecast period of 2022 to 2029 due to enhanced bioavailability and rapid onset action.
  • On the basis of end user, the global exosome therapeutics market is segmented into research and academic institutes, hospitals and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the global exosome therapeutics market growing with the highest CAGR of 17.1% in the forecast period of 2022 to 2029 due to rise in research and development of exosomes and support from government in funding, for the development of exosome therapeutics are predicted to dominate the market.

Major Players

Data Bridge Market Research recognizes the following companies as the major exosome therapeutics market players in exosome therapeutics market are Church & Dwight Co., Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (U.S.), AstraZeneca (U.S.), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (U.S.), CELGENE CORPORATION (U.S.), Sanofi (France), Johnson & Johnson Services, Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (U.S.), among others.

Exosome Therapeutics Market

Market Development

  • In November 2020, Exopharm introduced the LEAP technology. The technology proved to be an innovation in exosome therapeutics. The technology helps to purify the extracellular vehicles (EVs) of exosomes. This technology would enable the easily scalable production of exosomes
  • In September 2020, the Avalon Globocare Corp had introduced the mesenchymal stromal cell (MSC) therapeutic platform. Avalon’s mesenchymal stromal cell (MSC) therapeutic platform represents the culmination of vast research and development activities, leveraging the company’s scientific and clinical expertise in cellular therapy and stem cell-derived exosome (ACTEXTM) applications
  • In January 2020, Aegle Therapeutics announced USD 4 million financing to fund the Stem Cell Exosome Clinical Trial to treat Orphan Disease Dystrophic Epidermolysis Bullosa. Aegle's capital raise would support the first clinical trial in the U.S. using exosomes isolated from allogeneic mesenchymal stem cells as therapy
  • In April 2021, Capricor Therapeutics had signed an agreement with Johns Hopkins University to expand the exosome platform technology portfolio. The exosome platform technology portfolio would include the engineered exosomes for vaccines and therapeutics as part of the company’s exosome technology portfolio. The agreement would allow Capricor Therapeutics the worldwide right to engineer exosomes for vaccines and therapeutics
  • In January 2019, Jazz Pharmaceuticals and Codiak BioSciences had announced a strategic collaboration for research, development, and commercialization engineered exosomes to create therapies for malignant cancers. The partnership would strengthen the Jazz Pharmaceuticals collaboration with a novel therapeutic approach, which  has the potential to provide transformational benefit to a subgroup of patients with modulations in well-validated non-drug targets

Regional Analysis

Geographically, the countries covered in the exosome therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in exosome therapeutics market during the forecast period

North America dominated the exosome therapeutics market because of the presence of FDA-approved wound debridement devices and health remuneration policies. North America will continue to dominate the exosome therapeutics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the increasing healthcare expenditure.

Asia-Pacific is estimated to be the fastest growing region in exosome therapeutics market

Asia-Pacific is expected to grow during the forecast period due to the improvement in healthcare architecture and collaborations between healthcare organizations and market players in this region. In addition, the growing presence of major market players and rising disposable income are expected to propel the market's growth rate in this region.

For more detailed information about the exosome therapeutics market report, click here – https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market